 |
| Author | Post |
|---|
Meg Mangin R.N.
Research Team
|
Posted: Tue Sep 20th, 2005 02:04 |
|
"People With Inflammatory Bowel Disease More Likely to Suffer From Debilitating Respiratory and Nerve Disorders"
http://tinyurl.com/drep7
BETHESDA, MD -- September 1, 2005 -- According to two studies published today in the American Gastroenterological Association (AGA) journal Gastroenterology, people with inflammatory bowel disease are more prone to developing severe disorders of the respiratory and nervous systems. The studies found an increase in the prevalence of asthma, arthritis, chronic renal disease, multiple sclerosis and psoriasis, among other disorders. "These studies remind us that the effects of inflammatory bowel disorders extend to every corner of the body, including the lungs and central nervous system," said Edward V. Loftus, Jr., MD, author of an editorial appearing in this month's journal and associate professor of medicine at the Mayo Clinic College of Medicine. "The findings lend credence to the concept that patients with one chronic inflammatory condition are more likely than the general population to develop another." Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis and Crohn's disease. According to the most recent data from the National Health Interview Survey, there are more than two million prevalent cases of Crohn's disease and more than one million cases of ulcerative colitis in the U.S. Ulcerative colitis, a condition in which the lining of the large intestine becomes inflamed and ulcerated, most commonly affects people between 15 and
40 years of age. Common symptoms include abdominal cramps, bloody diarrhea, fever, weight loss and rectal bleeding. People with chronic, severe ulcerative colitis are at an increased risk of developing colorectal cancer. Crohn's disease causes chronic inflammation of the intestinal wall. While the cause of Crohn's is relatively unknown, it usually starts during the teenage years or early adulthood and is characterized by pain in the abdomen, diarrhea and weight loss. Researchers: Patients with IBD More Likely to Be Diagnosed with Multiple Sclerosis
(Increased Risk of Demyelinating Diseases in Patients with Inflammatory Bowel Disease, Gupta, et al.) A possible association between inflammatory bowel disease and multiple sclerosis (MS) has been suspected for decades, but previous studies have lacked the statistical power to confirm the relationship. A study published in this month's Gastroenterology is the first to confirm a nearly two-fold increased risk of multiple sclerosis in IBD patients. In addition to MS, researchers from the University of Pennsylvania found an association between IBD, optic neuritis and other demyelinating disorders. Patients being treated with anti-TNF alpha therapies, such as Remicade and Humira, were previously thought to be the only ones with an increased risk of developing these neurological disorders. As a result, clinician and patient label warnings were added to this class of drugs in 2004. Study authors say the causal relationship between these drugs and demyelinating disorders has not clearly been established because of the small amount of data available from controlled clinical trials. "While our study findings do not refute an association between anti-TNF alpha medications and these disorders, they point out that IBD patients appear to have an increased risk of multiple sclerosis even when they are not being treated with these medications," said James D. Lewis, MD, MSCE, study author from the University of Pennsylvania. "The development of neurologic symptoms in patients with IBD should prompt their physician to look for evidence of multiple sclerosis and other nervous system disorders." This study identified more than 20,000 patients from the UK's General Practice Research Database diagnosed with Crohn's disease and ulcerative colitis between January
1988 and October 1997. Each study subject was then matched to four controls, making for an inclusion of about 80,000 control subjects without IBD. The odds of an IBD patient being diagnosed with multiple sclerosis, optic neuritis and other demyelinating disorders was found to be 1.7 times as high as those patients without IBD. If the association is confirmed by other studies, researchers believe findings may help to identify common genetic or environmental factors contributing to the development of Crohn's and ulcerative colitis. People with Crohn's and Colitis at Greater Risk of Asthma, Researchers Say (The Clustering of Other Chronic Inflammatory Diseases in IBD: A Population-Based Study, Bernstein, et al.) In a similar study also published in this month's Gastroenterology, Canadian researchers looked at the relationship between IBD and common respiratory and neurological diseases. Results of this study suggest that the people with IBD have a significantly increased prevalence of asthma, bronchitis, arthritis and psoriasis. While some of these co-morbidities have been found previously, this study is the first to discover a significantly higher prevalence of asthma in IBD patients compared with non-IBD patients. "People with IBD are 1.5 times as likely to have asthma as people in the general population," said Charles N. Bernstein, MD, lead study author from the University of Manitoba in Canada. "Airway diseases are the second most common chronic inflammatory disease assessed in patients with either Crohn's disease or ulcerative colitis." Study data comes from the University of Manitoba IBD database, which included
8,072 people diagnosed with IBD over a 19-year period. Each of these people was matched randomly with 10 members of the general population by age, gender and geographic location. Ulcerative colitis patients were
50 to 70 percent more likely than the general population to have asthma, while Crohn's patients were about 30 to 40 percent more likely. Overall, people with IBD had a significantly higher prevalence than the general population for the following disorders: asthma, bronchitis, arthritis, multiple sclerosis, chronic renal disease, psoriasis and pericarditis. This study is the largest population-based study to assess the co-morbidity of these important immune-based diseases. Differences were not only found between the two diseases, but also in gender and age. Females had a greater percentage of pulmonary co-morbidities than males and more old people had bronchitis. "The findings from this study highlight an often overlooked association between intestinal disorders and the respiratory system," said Loftus. "Long-term consequences of untreated pulmonary involvement in IBD are substantial and physicians should at least follow-up respiratory complaints with pulmonary function tests." More information on inflammatory bowel disease is available at http://www.gastro.org. About the Studies Increased Risk of Demyelinating Diseases in Patients with Inflammatory Bowel Disease, Gupta, et al. Researchers from the University of Pennsylvania conducted a retrospective cross-sectional study and a cohort study to examine the association of IBD and multiple sclerosis, demyelination and optic neuritis to determine if these conditions are more common in IBD patients than non-IBD patients. The General Practice Research Database was used to gather the study population, which consisted of 20,173 patients from the United Kingdom with ulcerative colitis or Crohn's disease diagnoses between January 1988 and October 1997. Support for this research was provided by the National Institutes of Health. The Clustering of Other Chronic Inflammatory Diseases in IBD: A Population-Based Study, Bernstein, et al. Researchers at the University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre in Canada conducted a population-based study to assess the number of additional chronic inflammatory conditions in patients with inflammatory bowel disease. The study population was derived from the University of Manitoba IBD database, which includes all people in the Manitoba health care system with a Crohn's disease and ulcerative colitis diagnosis. The study population consisted of 8,072 people with IBD diagnoses between April 1, 1984 and March 31, 2003. This research was partially supported by the Crohn's and Colitis Foundation of Canada and the Canadian Institutes of Health Research. SOURCE: American Gastroenterological Association
|
Meg Mangin R.N.
Research Team
|
Posted: Tue Sep 20th, 2005 02:38 |
|
(filelink)
Uveitis
Crohn's disease uveitis. Parasitization of vitreous leukocytes by mollicute-like organisms.
Johnson LA, Wirostko E, Wirostko WJ.
http://tinyurl.com/dh8th
"Uveitis is a symptom, and has many identified causes and associations at this point. Some cases are widely accepted to be due to bacteria or viruses. Other cases are associated with “autoimmune diseases” like Crohns disease and rheumatic arthritis. I suspect that these other cases are due to CWD bacteria. There are several interesting papers that explore this. The researchers found cell-wall deficient bacteria (sometimes called mollicute-like organisms) in the vitreous fluid of patients with sardoidosis, Crohn’s disease, ulcerative colitis, juvenile rheumatoid arthritis, etc."
Margo
|
Aussie Barb
Research Team
| Joined: | Thu Jul 22nd, 2004 |
| Location: | Australia |
| Posts: | 19385 |
| Status: |
Online
|
|
Posted: Thu Oct 6th, 2005 19:51 |
|
High 1,25-D and osteoporosis in Crohn's disease
(filelink)
Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density
Alternative Medicine Review, Sept, 2004 by M.T> Abreu, V. Kantorovich, E.A. Vasiliauskas
____________________
Barb: Dx Inflammatory Disease Endocrine Imbalance 2003| 24+ years not Dx| ABCofMP
|
Aussie Barb
Research Team
| Joined: | Thu Jul 22nd, 2004 |
| Location: | Australia |
| Posts: | 19385 |
| Status: |
Online
|
|
Posted: Thu Oct 27th, 2005 20:56 |
|
Mycobacteria avium subspecies paratuberculosis (MAP) is the pathogen suspected of causing Crohn's disease.
Kenc wrote:
This pathogen was suspected in the early part of the last century soon after Crohn's disease was first identified. However, since researchers could not isolate it in Crohn's disease patients they gave up and turned to the concept of Crohn's disease being an immune disorder and so began the big push for immunosuppresive drugs.
Within the last decade there has been a resurgence of interest in MAP. Most Crohn's patients testing positive for MAP (about 45%) have responded well to long term antibiotic therapy in clinical trials (see research by Ira Shafran and by T. Borody). Their response was better than any immunosuppresive drug therapy I know. However, since not all Crohn's patients tested positive for MAP the medical community has remained skeptical of the claim that Crohn's disease is caused by MAP.
I believe the pathogenesis behind the Marshall Protocol includes the infection by one or more types of bacteria. That would account for the other 55% of Crohn's patients who didn't test positive for MAP. Furthermore the MP should work better than an antibiotic treatment for MAP alone since it would help the immune system to eradicate the other types of bacterium that could be present as well along with MAP.
I tested positive for two other types of bacteria other than MAP. One type of these bacterium comes from tics. I did not take a test for MAP. So, my case is evidence that a Crohn's patient can have non-MAP infections as well.
In spite of the increasing evidence for a microbial cause of Crohn's disease, most (>95% I believe) of the research money available for Crohn's disease, including money from charitable organizations, appears to be directed towards the development of immunosuppressive drugs. The latest craze seems to be for TNF-alpha blockers like Remicade.
The most amazing research I've seen was for MS patients. The idea was to kill all the white blood cells in an MS patient and then use stem cells taken earlier from the patient to repopulate the white blood cells. Of course about half of the patients died. This is modern medical research at its finest! It worked out OK for those that survived. Looking at this with MP eyes, I can see this as a drastic way of getting rid of CWD bacterium in the white blood cells - kill all the cells.
____________________
Barb: Dx Inflammatory Disease Endocrine Imbalance 2003| 24+ years not Dx| ABCofMP
|
Meg Mangin R.N.
Research Team
|
Posted: Thu Nov 10th, 2005 22:06 |
|
Targeted Antibiotics Lead to Long-lasting Improvement in IBS Symptoms
(filelink)
Source: Cedars-Sinai Medical Center
Released: Tue 08-Nov-2005, 14:00 ET
Libraries Medical News
Keywords IBS, IRRITABLE BOWEL SYNDROME, SIBO
Description
Researchers at Cedars-Sinai Medical Center have found that a nonabsorbable antibiotic – one that stays in the gut – may by be an effective long-term treatment for irritable bowel syndrome (IBS), a disease affecting more than an estimated 20 percent of Americans. The findings, which showed that participants benefited from the antibiotic use even after the course of treatment ended, support previously published research identifying small intestine bacterial overgrowth (SIBO) as a possible cause of the disease.
The research was presented at the recent American College of Gastroenterology's annual meeting in Honolulu, HI.
LOS ANGELES (Nov. 8, 2005) – Researchers at Cedars-Sinai Medical Center have found that a nonabsorbable antibiotic – one that stays in the gut – may be an effective long-term treatment for irritable bowel syndrome (IBS), a disease affecting more than an estimated 20 percent of Americans. The findings, which showed that participants benefited from the antibiotic use even after the course of treatment ended, support previously published research identifying small intestine bacterial overgrowth (SIBO) as a possible cause of the disease.
The research was presented at the recent American College of Gastroenterology's annual meeting in Honolulu, HI.
"This study is important as it is the first to show that the use of targeted antibiotics results in a more significant and long-lasting improvement in IBS symptoms," said Mark Pimentel, M.D., first author on the study and director of the GI Motility Program at Cedars-Sinai. "These results clearly show that antibiotics offer a new treatment approach – and a new hope – for people with IBS."
The randomized, double blind study involved 87 patients. Those on the rifaximin experienced a 37 percent overall improvement of their IBS symptoms as compared to 23 percent on the placebo. Among study subjects whose primary symptom was diarrhea, those on the antibiotic showed more than twice the improvement of those on the placebo (49 percent vs. 23 percent). Patients received the drug (or placebo) for 10 days and were then followed for a total of 10 weeks. Participants kept a stool diary, took a questionnaire and were given methane breath tests. The positive effects of the drug were shown to continue throughout most of the 10-week study, not just during the actual antibiotic course.
Because the cause of IBS has been elusive, treatments for the disease have historically focused on reducing its symptoms – diarrhea and constipation – by giving medications that either slow or speed up the digestive process. In 2000, Pimentel linked bloating, the most common symptom of IBS, to bacterial fermentation, showing that small intestine bacteria overgrowth (SIBO) may be the causative factor in IBS (The American Journal of Gastroenterology, Dec. 2000).
To show evidence of small intestine bacterial overgrowth, participants in both studies were given a lactulose breath test, which monitors the level of hydrogen and methane (the gases emitted by fermented bacteria) on the breath. In the first study, an abnormal breath methane profile was shown to be 100 percent predictive of constipation-predominant IBS. In the current study, the correlation between the amount of methane and the amount of constipation was confirmed, another key finding.
"We were pleased – but not surprised – with the results of this study," said Pimentel. "The next step is to start larger, multi-centered studies to confirm the positive results of this study, which suggest that people can benefit from targeted antibiotic treatment for their IBS."
Irritable Bowel Syndrome is an intestinal disorder that causes abdominal pain or discomfort, cramping or bloating and diarrhea and constipation. It is a long-term condition that usually begins in adolescence or in early adult life. Episodes may be mild or severe and may be exacerbated by stress. It is one of the top ten most frequently diagnosed conditions among U.S. physicians and affects women more often than men.
Other authors from Cedars-Sinai include Sandy Park, B.A., Yuthana Kong M.P.H. and Robert Wade. Sunanda V. Kane from the University of Chicago also participated in the study.
Rifaximin is made by Salix Pharmaceuticals, Inc. Funding for the study was provided by Salix Pharmaceuticals, Inc.
One of only five hospitals in California whose nurses have been honored with the prestigious Magnet designation, Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For 17 consecutive years, it has been named Los Angeles' most preferred hospital for all health needs in an independent survey of area residents. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. It ranks among the top 10 non-university hospitals in the nation for its research activities and was recently fully accredited by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP). Additional information is available at http://www.cedars-sinai.edu
© 2005 Newswise. All Rights Reserved.
Newswise | Targeted Antibiotics Lead to Long-lasting Improvement in IBS Symptoms
http://www.newswise.com/articles/view/515982/
|
Aussie Barb
Research Team
| Joined: | Thu Jul 22nd, 2004 |
| Location: | Australia |
| Posts: | 19385 |
| Status: |
Online
|
|
Posted: Tue Dec 6th, 2005 22:48 |
|
PERSONAL:
Members working with their Drs re Crohn's Disease
Crohn's and MP Journey Phase 1 KenC working with his Dr
June 2008: I believe I've made some progress on my disease so far. I'm steriod-free and I no longer have significant abdominal pain. One way or the other I will get well.
August 2008:
*My dentist is going to take pictures next week so that he has a record of the amazing improvement in my gums - they're growing back!
*My optometrist has given me a new lower prescription - 1 diopter less for myopia.
*The arthritis in my hands has disappeared.
*Most of the psoriasis has disappeared.
~ KenC
Crohn's Success Jeanne
____________________
Barb: Dx Inflammatory Disease Endocrine Imbalance 2003| 24+ years not Dx| ABCofMP
|
Meg Mangin R.N.
Research Team
|
Posted: Fri Mar 17th, 2006 15:43 |
|
Doctor: Infection is at root of Crohn's disease -- Newsday.com
Aussie-native Dr. Thomas Borody, who recently was awarded the Marshall Prize in Australia for innovative scientific research and who will lecture 3/06 on Long Island, has proposed that Crohn's disease, is caused by Mycobacterium avium paratuberculosis (or MAP for short). The microbe is a distant relative of the tuberculosis and leprosy bacteria.
|
Aussie Barb
Research Team
| Joined: | Thu Jul 22nd, 2004 |
| Location: | Australia |
| Posts: | 19385 |
| Status: |
Online
|
|
Posted: Wed Nov 15th, 2006 00:52 |
|
Dr Marshall posted re
(filelink)
Host Defences - UCSD 2006
University of California-San Diego
Frontiers of Clinical Investigation Conference
Host Defense 2006: From Bench to Bedside
Oct5-7 La Jolla, CA
...one of the presentations was so compelling I have taken the effort to put it online. It explains how the antimicrobial peptides (the body's own antibiotics) are employed against the pathogens which cause Crohn's disease.
Many of you have heard me talk about how important it is to get the VDR Nuclear Receptor working properly (one of the things Benicar does) because the VDR is responsible for the Cathelicin Anti-Microbial Peptides. It is also responsible for transcribing the genes of the Beta Defensins.
This presentation explains how those, and the other Defensins, are important, and I think that those of you who track the science will find it very interesting indeed.
The 24 Mbyte RealVideo 9 presentation runs for 30 minutes. You can stream it from URL
http://autoimmunityresearch.org/crohns.ram
and the more technically astute can download the whole presentation by right-clicking on this link.
____________________
Barb: Dx Inflammatory Disease Endocrine Imbalance 2003| 24+ years not Dx| ABCofMP
|
Meg Mangin R.N.
Research Team
|
Posted: Sat Dec 9th, 2006 23:10 |
|
Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease.
(filelink)
Silvennoinen J. J Intern Med. 1996 Feb;239(2):131-7.
Department of Internal Medicine, University of Oulu, Finland.
OBJECTIVES. To explore the relationships between vitamin D intake, serum parathyroid hormone (PTH) and 25-hydroxyvitamin D (250HD) concentrations, and bone mineral density (BMD) in inflammatory bowel disease (IBD). SETTING. A university hospital clinic in Finland. SUBJECTS. One hundred and fifty randomly selected patients with IBD from the hospital register and 73 healthy controls. MEASUREMENTS. BMD of the lumbar spine and the proximal femur was measured with dual energy X-ray absorptiometry. Vitamin D intake and serum levels of 250HD and PTH were determined. RESULTS. The IBD patients had a lower serum 250HD concentration (28.4 [SD 12.0] nmol L-1) than the controls (36.1 [16.7] nmol L-1; P = 0.001), whereas no differences in the vitamin D intake or the serum PTH levels were found. The serum 250HD concentrations and the vitamin D intake of the patients with ulcerative colitis (n = 67) were similar to those of the Crohn's disease patients (n = 76). The patients with Crohn's disease of the small bowel had slightly, but not significantly, lower serum 250HD concentrations (25.6 [11.0] nmol L-1) than the other Crohn's disease patients (31.4 [14.3] nmol L-1; P = 0.061). In the IBD patients, the vitamin D intake and the serum 250HD and PTH concentrations were not associated with BMD. CONCLUSIONS. Patients with IBD have lower serum levels of 250HD than healthy controls, but similar serum PTH concentrations and vitamin D intake. Vitamin D intake, and the serum levels of 250HD and PTH are not associated with BMD, and malabsorption is unlikely to be a major factor in the aetiology of bone loss in unselected IBD patients.
PMID: 8568480 [PubMed - indexed for MEDLINE]
|
Meg Mangin R.N.
Research Team
|
Posted: Thu Dec 27th, 2007 21:32 |
|
[filelink]
Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury.
BMC Immunol. 2007 Mar 30;8:5.
Froicu M, Cantorna MT.Department of Veterinary and Biomedical Sciences, Pathobiology Graduate Program, The Pennsylvania State University, University Park, PA 16802, USA.
BACKGROUND: The active form of vitamin D (1,25(OH)2D3) has been shown to inhibit development of inflammatory bowel disease (IBD) in IL-10 KO mice. Here, the role of the vitamin D receptor (VDR) and 1,25(OH)2D3 in acute experimental IBD was probed. RESULTS: VDR KO mice were extremely sensitive to dextran sodium sulfate (DSS) and there was increased mortality of the VDR KO mice at doses of DSS that only caused a mild form of colitis in wildtype (WT) mice. DSS colitis in the VDR KO mice was accompanied by high colonic expression of TNF-alpha, IL-1 alpha, IL-1beta, IL-12, IFN-gamma, IL-10, MIP-1alpha and KC. DSS concentrations as low as 0.5% were enough to induce bleeding, ulceration and weight loss in VDR KO mice. VDR KO mice failed to recover following the removal of DSS, while WT mice showed signs of recovery within 5 days of DSS removal. The early mortality of DSS treated VDR KO mice was likely due to perforation of the bowel and resulting endotoxemia. VDR KO mice were hyper-responsive to exogenously injected LPS and cultures of the peritoneal exudates of moribund DSS treated VDR KO mice were positive for bacterial growth. 1,25(OH)2D3 in the diet or rectally decreased the severity and extent of DSS-induced inflammation in WT mice.
CONCLUSION: The data point to a critical role for the VDR and 1,25(OH)2D3 in control of innate immunity and the response of the colon to chemical injury.
PMID: 17397543 [PubMed - indexed for MEDLINE]
|
Current time is 08:43 | |
|
|
|
|
